References
- Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909–915 (2004).
- Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl Acad. Sci. 101,14639–14645 (2004).
- Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Irnmunol. 3(7), 611–618 (2002).
- Chakaborty M, Abrams SI, Coleman CN et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64(12), 4328–4337 (2004).
- Durrant LG, Spendlove I. Cancer vaccines entering Phase III clinical trials. Expert Opin. Emerg. Drugs 8(2), 489–500 (2003).
- Folkman J, Kalluri R. Cancer without disease. Nature 427(6977), 787 (2004).
- Pardoll D, Allison JP. Nature Med. 10(9), 887–892 (2004).
- Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 305, 200 (2004).
Websites
- National Cancer Institute ioi National Cancer Institute www.nci.nih.gov Accessed November, 2004.